Corline Biomedical
Corline Biomedical is a Swedish medical technology company focused on CHS™, a heparin-based surface technology used to make blood-contacting medical devices more biocompatible. The company develops and supplies products, reagents, and licensing-based solutions for device manufacturers, with a commercial focus in cardiovascular and catheter-based applications.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueHeparin-based surface technology used to improve blood compatibility in medical devices.
Commercially supplied products and reagents used in coating and device workflows.
Longer-term agreements that grant customers rights to use Corline's technology and supply chain.
Customers
Corline sells primarily to medical device companies that need blood-compatible surfaces for catheters and other blood-contacting products. The most visible end market in the reports is pulsed field ablation (PFA) for cardiac arrhythmia treatment, where CHS™ is used in catheter-based systems. The company also addresses broader medtech customers that may adopt CHS™ as a standard antithrombotic solution.
Buy CHS™-enabled solutions for pulsed field ablation catheter systems because blood compatibility is critical in cardiac procedures.
Purchase products, reagents, and technology access for blood-contacting devices that need antithrombotic surface treatment.
Buy recurring products and reagents used in ongoing device production and development workflows.
Evaluate CHS™ as a standard surface solution for broader device categories beyond the current core accounts.
Strategy
Corline's strategy is to expand commercial deliveries of products and reagents while broadening CHS™ adoption across more medical device customers. A central priority is the Kardium Globe® PFA program, which can validate the technology in a fast-growing cardiac ablation market and support wider customer adoption. The company also aims to convert its technology into longer-term licensing and supply relationships that can scale beyond a single device platform.
Recurring commercial sales improve visibility and support broader adoption of the technology.
A successful platform relationship can anchor volume and validate CHS™ in a fast-growing market.
A wider customer base reduces dependence on any single program and expands addressable demand.
Geography
Corline is headquartered in Sweden and appears to operate as a small, internationally oriented medtech supplier. The reports highlight commercial focus on the U.S. market through CHS™ supply relationships, while the customer base is tied to global medical device development and manufacturing. Geography matters because regulatory approval, customer qualification, and device commercialization are all tied to specific markets and OEM programs.
Risks
Corline depends on successful customer qualification, regulatory approvals, and adoption of its CHS™ technology in a specialized medtech market. The business is exposed to concentration risk in a small number of programs, as well as execution risk if expected customer uptake or device commercialization is delayed. Like other early commercial medtech suppliers, it also faces technical, regulatory, and reimbursement-related uncertainty in end markets such as cardiac ablation.
Medical device adoption depends on approvals, validation, and customer qualification cycles.
Exposure: PFA and catheter-based applications
A limited number of commercial programs can materially affect revenue if one account slows or ends.
Exposure: Kardium Globe® and related medtech customers
CHS™ must prove performance and reliability across customer programs before scaling broadly.
Exposure: New medtech customer adoption
A meaningful part of the growth case is tied to one fast-growing but specialized end market.
Exposure: Pulsed field ablation
Accounting
Judgemental itemsCommercial deliveries, product sales, and contract-based arrangements may be recognized at different points in time.
Impact: Can cause quarter-to-quarter volatility in reported revenue
The company reports a changing mix between commercial deliveries and other revenue sources.
Impact: Affects gross margin profile and comparability
With low absolute revenue, timing differences can materially change quarterly trends.
Impact: Makes trend analysis sensitive to one-off deliveries
Similar listed companies
Publicly listed companies with a comparable business focus.
SeaStar Medical Holding Corp
ICUCW · Surgical & Medical Instruments & Apparatus
SeaStar Medical Holding Corp is a U.S.-based medical device company focused on therapies that treat acute and chronic kidney injury through selective cytopheretic devices.
Corcept Therapeutics Incorporated
CORT · Pharmaceutical Preparations
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym…
Lifecore Biomedical, Inc
LFCR · Pharmaceutical Preparations
Lifecore Biomedical is a U.S.-based contract development and manufacturing organization focused on complex sterile injectable products and pharmaceutical-grade hyaluronic acid (HA).
CorMedix Inc.
CRMD · Pharmaceutical Preparations
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
Getinge
GETI-B · Health Care
Getinge AB is a global provider of products and solutions for healthcare and life sciences, focusing on intensive care, cardiovascular procedures, operating…
Last updated: 24/09/2026